Literature DB >> 19818750

Model of methadone-induced hyperalgesia in rats and effect of memantine.

Justin L Hay1, Jahangir Kaboutari, Jason M White, Abdallah Salem, Rod Irvine.   

Abstract

Methadone used for opioid dependence therapy is associated with increased pain sensitivity. This study aimed to investigate whether methadone administration lowers nociceptive threshold in adult male Sprague-Dawley (SD) rats, and if this threshold could be altered by the NMDA receptor antagonist memantine. Rats were implanted with osmotic pumps delivering 1mg/kg/day methadone (n=6), or saline placebo (n=6) (0.51 microl/h). A separate cohort of rats received either methadone 1mg/kg/day (n=8) or methadone 1mg/kg/day with 20mg/kg/day memantine (n=8). Nociception was measured by the Hargreave's paw withdrawal test. Baseline nociception was measured on day 0 prior to osmotic pump implantation and was measured daily for the following 21 days. Osmotic pumps were removed following nociceptive testing on day 14. Methadone only treated rats had a mean paw withdrawal latency significantly lower than the corresponding values for saline on days 8, 9, 10, 11, 12, 14, and 17 (P<0.05). At all other time points the mean paw withdrawal latency was not significantly different from saline (P>0.05). Paw withdrawal latency of rats treated with methadone co-administered with memantine did not differ significantly compared to methadone only (P>0.05). This demonstrates that methadone induces hyperalgesia in the SD rat yet this hyperalgesia resolves following discontinuation of methadone administration. Furthermore, memantine does not alter the development of methadone-induced hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818750     DOI: 10.1016/j.ejphar.2009.09.056

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease.

Authors:  C Patrick Carroll; Sophie Lanzkron; Carlton Haywood; Kasey Kiley; Megan Pejsa; Gyasi Moscou-Jackson; Jennifer A Haythornthwaite; Claudia M Campbell
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

Review 4.  Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?

Authors:  D Andrew Tompkins; Claudia M Campbell
Journal:  Curr Pain Headache Rep       Date:  2011-04

5.  The effect of intermittent alcohol vapor or pulsatile heroin on somatic and negative affective indices during spontaneous withdrawal in Wistar rats.

Authors:  Angela M Williams; Daniel J Reis; Alexa S Powell; Louis J Neira; Kathryn A Nealey; Cole E Ziegler; Nina D Kloss; Jessica L Bilimoria; Chelsea E Smith; Brendan M Walker
Journal:  Psychopharmacology (Berl)       Date:  2012-03-31       Impact factor: 4.530

6.  The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males.

Authors:  David Andrew Tompkins; Michael T Smith; George E Bigelow; Ruin Moaddel; Swarajya Lakshmi Vatem Venkata; Eric C Strain
Journal:  Clin J Pain       Date:  2014-01       Impact factor: 3.442

Review 7.  Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia.

Authors:  D Eric Brush
Journal:  J Med Toxicol       Date:  2012-12

Review 8.  Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.

Authors:  Arden G Vanderwall; Erin D Milligan
Journal:  Front Immunol       Date:  2019-12-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.